English

ALAUNOS THERAPEUTICS, INC.

EDGAR

TCRT Current report (8-K) · filed 2026-10-23

Annual consolidated revenue for 2025: about USD 5K, using the latest reported figures. The previous period, 2024, was about USD 10K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-300 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -1331000 USD Source
Operating Cash Flow: -1031000 USD Source

Cash and cash equivalents: 124 thousand USD 2026-06-30 Source
Exact value

124000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 2.49 million shares 2026-06-30 Source
Exact value

2486140 shares

Reported share-count change

19.83% · 411 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

2074746 shares · 2025-06-30· Source
2486140 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

3 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 0 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 5000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 2000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 0 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 0 USD · 2026-04-01 – 2026-06-30 Source

Net income

-4.01 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -1159000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -4176000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -3283000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -1006000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -952000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-2.73 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -2317000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -1473000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -2869000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -2317000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -1031000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -1331000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -1031000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-23.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 9 of 11 periods available· newest 2025-12-31
Total liabilities: 9 of 11 periods available· newest 2025-12-31
Current assets: 9 of 11 periods available· newest 2025-12-31
Current liabilities: 9 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 9 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-50%

Prior period

USD 10,000

2024-01-01 – 2024-12-31
Current period

USD 5,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

5000 − 10000 = -5000 USD

10000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
5000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ALAUNOS THERAPEUTICS, INC. · 2025-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Year-over-year change in Revenue: -5000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 5000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1685451 Filing: 000119312526134720 Input fundies:Revenue: 10000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1686333 Filing: 000119312526134720
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 503,000

Prior period

−USD 4.68 million

2024-01-01 – 2024-12-31
Current period

−USD 4.18 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-4176000 − -4679000 = 503000 USD

-4679000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-4176000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ALAUNOS THERAPEUTICS, INC. · 2025-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Year-over-year change in Net income: 503000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -4176000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1741275 Filing: 000119312526134720 Input fundies:NetIncome: -4679000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1743136 Filing: 000119312526134720
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 2.1 million

Prior period

−USD 4.97 million

2024-01-01 – 2024-12-31
Current period

−USD 2.87 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-2869000 − -4971000 = 2102000 USD

-4971000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-2869000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ALAUNOS THERAPEUTICS, INC. · 2025-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Year-over-year change in Operating cash flow: 2102000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -2869000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1545671 Filing: 000119312526134720 Input fundies:OperatingCashFlow: -4971000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1547620 Filing: 000119312526134720
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+USD 98,000

Prior period

USD 0

2024-01-01 – 2024-12-31
Current period

USD 98,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

98000 − 0 = 98000 USD

0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
98000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ALAUNOS THERAPEUTICS, INC. · 2025-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Year-over-year change in Capital expenditure: 98000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 98000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1552538 Filing: 000119312526134720 Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1554282 Filing: 000119312526134720
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 5,000 100% of revenue
Operating costs Derived USD 4.23 million 84,600% of revenue
Operating income −USD 4.23 million −84,500% of revenue
Tax, interest and other Derived −USD 49,000 −980% of revenue
Net income −USD 4.18 million −83,520% of revenue

Cash

Operating cash flow −USD 2.87 million −57,380% of revenue
Capital expenditure USD 98,000 1,960% of revenue
Free cash flow Derived −USD 2.97 million −59,340% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 2,509% of revenue.
2017 Operating loss: operating costs were 436% of revenue.
2018 Operating loss: operating costs were 37,022% of revenue.
2020 Not shown: operating income or net income is not reported.
2021 Operating loss: operating costs were 19,487% of revenue.
2022 Operating loss: operating costs were 1,311% of revenue.
2023 Operating loss: operating costs were 685,440% of revenue.
2024 Operating loss: operating costs were 48,220% of revenue.
2025 Operating loss: operating costs were 84,600% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	6861000	172168000 Derived	-165307000	-10000 Derived	-165297000	-58876000 Derived	Source 2016-01-01 – 2016-12-31: 6861000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -165307000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -165297000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -58325000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 551000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	15900000	69393000 Derived	-53493000	830000 Derived	-54323000	-55406000 Derived	Source 2017-01-01 – 2017-12-31: 15900000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -53493000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -54323000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -54669000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 737000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	146000	54052000 Derived	-53906000	-789000 Derived	-53117000	-49916000 Derived	Source 2018-01-01 – 2018-12-31: 146000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -53906000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -53117000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -49457000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 459000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	0	80361000 Derived	-80361000	-385000 Derived	-79976000	-66791000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -80361000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -79976000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -57013000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 9778000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	400000	77949000 Derived	-77549000	1202000 Derived	-78751000	-64791000 Derived	Source 2021-01-01 – 2021-12-31: 400000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -77549000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -78751000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -61468000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 3323000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	2900000	38005000 Derived	-35105000	2625000 Derived	-37730000	-29448000 Derived	Source 2022-01-01 – 2022-12-31: 2900000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -35105000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -37730000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -29232000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 216000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	5000	34272000 Derived	-34267000	-29588000 Derived	-4679000	-30339000 Derived	Source 2023-01-01 – 2023-12-31: 5000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -34267000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -4679000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -30142000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 197000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	10000	4822000 Derived	-4812000	-133000 Derived	-4679000	-4971000 Derived	Source 2024-01-01 – 2024-12-31: 10000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -4812000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -4679000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -4971000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	5000	4230000 Derived	-4225000	-49000 Derived	-4176000	-2967000 Derived	Source 2025-01-01 – 2025-12-31: 5000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -4225000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -4176000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -2869000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 98000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 5K 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	6861000	Revenue: 6861000 Open source
20172017-12-31	Revenue	15900000	Revenue: 15900000 Open source
20182018-12-31	Revenue	146000	Revenue: 146000 Open source
20202020-12-31	Revenue	0	Revenue: 0 Open source
20212021-12-31	Revenue	400000	Revenue: 400000 Open source
20222022-12-31	Revenue	2900000	Revenue: 2900000 Open source
20232023-12-31	Revenue	5000	Revenue: 5000 Open source
20242024-12-31	Revenue	10000	Revenue: 10000 Open source
20252025-12-31	Revenue	5000	Revenue: 5000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-50% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 6861000 Open source
20172017-12-31	Year over year	131.7%	Revenue: 15900000 Open source Revenue: 6861000 Open source
20182018-12-31	Year over year	-99.1%	Revenue: 146000 Open source Revenue: 15900000 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 400000 Open source Revenue: 0 Open source
20222022-12-31	Year over year	625%	Revenue: 2900000 Open source Revenue: 400000 Open source
20232023-12-31	Year over year	-99.8%	Revenue: 5000 Open source Revenue: 2900000 Open source
20242024-12-31	Year over year	100%	Revenue: 10000 Open source Revenue: 5000 Open source
20252025-12-31	Year over year	-50%	Revenue: 5000 Open source Revenue: 10000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -84,500% 2025

Net margin -83,520% 2025

Free cash flow margin -59,340% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-2,409.4%	Operating Income: -165307000 Open source Revenue: 6861000 Open source
20172017-12-31	Operating margin	-336.4%	Operating Income: -53493000 Open source Revenue: 15900000 Open source
20182018-12-31	Operating margin	-36,921.9%	Operating Income: -53906000 Open source Revenue: 146000 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -80361000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	-19,387.3%	Operating Income: -77549000 Open source Revenue: 400000 Open source
20222022-12-31	Operating margin	-1,210.5%	Operating Income: -35105000 Open source Revenue: 2900000 Open source
20232023-12-31	Operating margin	-685,340%	Operating Income: -34267000 Open source Revenue: 5000 Open source
20242024-12-31	Operating margin	-48,120%	Operating Income: -4812000 Open source Revenue: 10000 Open source
20252025-12-31	Operating margin	-84,500%	Operating Income: -4225000 Open source Revenue: 5000 Open source
20162016-12-31	Net margin	-2,409.2%	Net Income: -165297000 Open source Revenue: 6861000 Open source
20172017-12-31	Net margin	-341.7%	Net Income: -54323000 Open source Revenue: 15900000 Open source
20182018-12-31	Net margin	-36,381.5%	Net Income: -53117000 Open source Revenue: 146000 Open source
20202020-12-31	Net margin	Not reported	Net Income: -79976000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	-19,687.8%	Net Income: -78751000 Open source Revenue: 400000 Open source
20222022-12-31	Net margin	-1,301%	Net Income: -37730000 Open source Revenue: 2900000 Open source
20232023-12-31	Net margin	-93,580%	Net Income: -4679000 Open source Revenue: 5000 Open source
20242024-12-31	Net margin	-46,790%	Net Income: -4679000 Open source Revenue: 10000 Open source
20252025-12-31	Net margin	-83,520%	Net Income: -4176000 Open source Revenue: 5000 Open source
20162016-12-31	Free cash flow margin	-858.1%	Revenue: 6861000 Open source Operating Cash Flow: -58325000 Open source Capital Expenditure: 551000 Open source
20172017-12-31	Free cash flow margin	-348.5%	Revenue: 15900000 Open source Operating Cash Flow: -54669000 Open source Capital Expenditure: 737000 Open source
20182018-12-31	Free cash flow margin	-34,189%	Revenue: 146000 Open source Operating Cash Flow: -49457000 Open source Capital Expenditure: 459000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -57013000 Open source Capital Expenditure: 9778000 Open source
20212021-12-31	Free cash flow margin	-16,197.8%	Revenue: 400000 Open source Operating Cash Flow: -61468000 Open source Capital Expenditure: 3323000 Open source
20222022-12-31	Free cash flow margin	-1,015.4%	Revenue: 2900000 Open source Operating Cash Flow: -29232000 Open source Capital Expenditure: 216000 Open source
20232023-12-31	Free cash flow margin	-606,780%	Revenue: 5000 Open source Operating Cash Flow: -30142000 Open source Capital Expenditure: 197000 Open source
20242024-12-31	Free cash flow margin	-49,710%	Revenue: 10000 Open source Operating Cash Flow: -4971000 Open source Capital Expenditure: 0 Open source
20252025-12-31	Free cash flow margin	-59,340%	Revenue: 5000 Open source Operating Cash Flow: -2869000 Open source Capital Expenditure: 98000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -2.9M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-58325000	Operating Cash Flow: -58325000 Open source
20172017-12-31	Operating cash flow	-54669000	Operating Cash Flow: -54669000 Open source
20182018-12-31	Operating cash flow	-49457000	Operating Cash Flow: -49457000 Open source
20202020-12-31	Operating cash flow	-57013000	Operating Cash Flow: -57013000 Open source
20212021-12-31	Operating cash flow	-61468000	Operating Cash Flow: -61468000 Open source
20222022-12-31	Operating cash flow	-29232000	Operating Cash Flow: -29232000 Open source
20232023-12-31	Operating cash flow	-30142000	Operating Cash Flow: -30142000 Open source
20242024-12-31	Operating cash flow	-4971000	Operating Cash Flow: -4971000 Open source
20252025-12-31	Operating cash flow	-2869000	Operating Cash Flow: -2869000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -3M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-58876000	Operating Cash Flow: -58325000 Open source Capital Expenditure: 551000 Open source
20172017-12-31	Free cash flow	-55406000	Operating Cash Flow: -54669000 Open source Capital Expenditure: 737000 Open source
20182018-12-31	Free cash flow	-49916000	Operating Cash Flow: -49457000 Open source Capital Expenditure: 459000 Open source
20202020-12-31	Free cash flow	-66791000	Operating Cash Flow: -57013000 Open source Capital Expenditure: 9778000 Open source
20212021-12-31	Free cash flow	-64791000	Operating Cash Flow: -61468000 Open source Capital Expenditure: 3323000 Open source
20222022-12-31	Free cash flow	-29448000	Operating Cash Flow: -29232000 Open source Capital Expenditure: 216000 Open source
20232023-12-31	Free cash flow	-30339000	Operating Cash Flow: -30142000 Open source Capital Expenditure: 197000 Open source
20242024-12-31	Free cash flow	-4971000	Operating Cash Flow: -4971000 Open source Capital Expenditure: 0 Open source
20252025-12-31	Free cash flow	-2967000	Operating Cash Flow: -2869000 Open source Capital Expenditure: 98000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

27.4% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	54.8%	Total Liabilities: 58325000 Open source Total Assets: 106348000 Open source
20172017-12-31	Liabilities / assets	55.3%	Total Liabilities: 58420000 Open source Total Assets: 105606000 Open source
20182018-12-31	Liabilities / assets	10%	Total Liabilities: 9487000 Open source Total Assets: 95051000 Open source
20202020-12-31	Liabilities / assets	15.3%	Total Liabilities: 22363000 Open source Total Assets: 146345000 Open source
20212021-12-31	Liabilities / assets	38.8%	Total Liabilities: 36809000 Open source Total Assets: 94865000 Open source
20222022-12-31	Liabilities / assets	40.6%	Total Liabilities: 26382000 Open source Total Assets: 64937000 Open source
20232023-12-31	Liabilities / assets	23.7%	Total Liabilities: 1956000 Open source Total Assets: 8263000 Open source
20242024-12-31	Liabilities / assets	25.1%	Total Liabilities: 692000 Open source Total Assets: 2755000 Open source
20252025-12-31	Liabilities / assets	27.4%	Total Liabilities: 813000 Open source Total Assets: 2966000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.45× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	6.63×	Current Assets: 104884000 Open source Current Liabilities: 15809000 Open source
20172017-12-31	Current assets / current liabilities	4.35×	Current Assets: 90783000 Open source Current Liabilities: 20856000 Open source
20182018-12-31	Current assets / current liabilities	8.89×	Current Assets: 84285000 Open source Current Liabilities: 9483000 Open source
20202020-12-31	Current assets / current liabilities	7.11×	Current Assets: 130589000 Open source Current Liabilities: 18368000 Open source
20212021-12-31	Current assets / current liabilities	4.91×	Current Assets: 78831000 Open source Current Liabilities: 16041000 Open source
20222022-12-31	Current assets / current liabilities	2.23×	Current Assets: 53799000 Open source Current Liabilities: 24166000 Open source
20232023-12-31	Current assets / current liabilities	4.22×	Current Assets: 8261000 Open source Current Liabilities: 1956000 Open source
20242024-12-31	Current assets / current liabilities	3.98×	Current Assets: 2755000 Open source Current Liabilities: 692000 Open source
20252025-12-31	Current assets / current liabilities	2.45×	Current Assets: 1988000 Open source Current Liabilities: 813000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 165.3 million Exact value Exact value: -165297000 USD 2016-01-01 – 2016-12-31: -165297000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALAUNOS THERAPEUTICS, INC. · 2016-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Net Income: -165297000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -165297000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312519063978/ziop-20181231.xml#124780 Filing: 000119312519063978 The citation records this snapshot. The page link may show a newer release later.	−USD 58.33 million Exact value Exact value: -58325000 USD 2016-01-01 – 2016-12-31: -58325000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALAUNOS THERAPEUTICS, INC. · 2016-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Operating Cash Flow: -58325000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -58325000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312519063978/ziop-20181231.xml#1605287 Filing: 000119312519063978 The citation records this snapshot. The page link may show a newer release later.	USD 551,000 Exact value Exact value: 551000 USD 2016-01-01 – 2016-12-31: 551000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALAUNOS THERAPEUTICS, INC. · 2016-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Capital Expenditure: 551000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 551000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312519063978/ziop-20181231.xml#131068 Filing: 000119312519063978 The citation records this snapshot. The page link may show a newer release later.	−USD 58.88 million Calculation and evidence -58325000 − 551000 USD Exact free cash flow: -58876000 USD 2016-01-01 – 2016-12-31: -58325000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 551000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALAUNOS THERAPEUTICS, INC. · 2016-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Free cash flow: -58876000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -58325000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312519063978/ziop-20181231.xml#1605287 Filing: 000119312519063978 Input fundies:CapitalExpenditure: 551000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312519063978/ziop-20181231.xml#131068 Filing: 000119312519063978 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 54.32 million Exact value Exact value: -54323000 USD 2017-01-01 – 2017-12-31: -54323000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALAUNOS THERAPEUTICS, INC. · 2017-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Net Income: -54323000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -54323000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312520058863/ziop-20191231.xml#140577 Filing: 000119312520058863 The citation records this snapshot. The page link may show a newer release later.	−USD 54.67 million Exact value Exact value: -54669000 USD 2017-01-01 – 2017-12-31: -54669000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALAUNOS THERAPEUTICS, INC. · 2017-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Operating Cash Flow: -54669000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -54669000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312520058863/ziop-20191231.xml#175251 Filing: 000119312520058863 The citation records this snapshot. The page link may show a newer release later.	USD 737,000 Exact value Exact value: 737000 USD 2017-01-01 – 2017-12-31: 737000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALAUNOS THERAPEUTICS, INC. · 2017-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Capital Expenditure: 737000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 737000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312520058863/ziop-20191231.xml#174844 Filing: 000119312520058863 The citation records this snapshot. The page link may show a newer release later.	−USD 55.41 million Calculation and evidence -54669000 − 737000 USD Exact free cash flow: -55406000 USD 2017-01-01 – 2017-12-31: -54669000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 737000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALAUNOS THERAPEUTICS, INC. · 2017-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Free cash flow: -55406000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -54669000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312520058863/ziop-20191231.xml#175251 Filing: 000119312520058863 Input fundies:CapitalExpenditure: 737000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312520058863/ziop-20191231.xml#174844 Filing: 000119312520058863 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 53.12 million Exact value Exact value: -53117000 USD 2018-01-01 – 2018-12-31: -53117000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALAUNOS THERAPEUTICS, INC. · 2018-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Net Income: -53117000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -53117000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446d10k.htm#2060617 Filing: 000119312521063387 The citation records this snapshot. The page link may show a newer release later.	−USD 49.46 million Exact value Exact value: -49457000 USD 2018-01-01 – 2018-12-31: -49457000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALAUNOS THERAPEUTICS, INC. · 2018-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Operating Cash Flow: -49457000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -49457000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446d10k.htm#1733902 Filing: 000119312521063387 The citation records this snapshot. The page link may show a newer release later.	USD 459,000 Exact value Exact value: 459000 USD 2018-01-01 – 2018-12-31: 459000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALAUNOS THERAPEUTICS, INC. · 2018-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Capital Expenditure: 459000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 459000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446d10k.htm#1738694 Filing: 000119312521063387 The citation records this snapshot. The page link may show a newer release later.	−USD 49.92 million Calculation and evidence -49457000 − 459000 USD Exact free cash flow: -49916000 USD 2018-01-01 – 2018-12-31: -49457000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 459000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALAUNOS THERAPEUTICS, INC. · 2018-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Free cash flow: -49916000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -49457000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446d10k.htm#1733902 Filing: 000119312521063387 Input fundies:CapitalExpenditure: 459000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446d10k.htm#1738694 Filing: 000119312521063387 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 117.8 million Exact value Exact value: -117796000 USD 2019-01-01 – 2019-12-31: -117796000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALAUNOS THERAPEUTICS, INC. · 2019-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Net Income: -117796000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -117796000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446d10k.htm#2060162 Filing: 000119312521063387 The citation records this snapshot. The page link may show a newer release later.	−USD 40.85 million Exact value Exact value: -40854000 USD 2019-01-01 – 2019-12-31: -40854000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALAUNOS THERAPEUTICS, INC. · 2019-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Operating Cash Flow: -40854000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -40854000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446d10k.htm#1733409 Filing: 000119312521063387 The citation records this snapshot. The page link may show a newer release later.	USD 284,000 Exact value Exact value: 284000 USD 2019-01-01 – 2019-12-31: 284000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALAUNOS THERAPEUTICS, INC. · 2019-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Capital Expenditure: 284000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 284000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446d10k.htm#1738213 Filing: 000119312521063387 The citation records this snapshot. The page link may show a newer release later.	−USD 41.14 million Calculation and evidence -40854000 − 284000 USD Exact free cash flow: -41138000 USD 2019-01-01 – 2019-12-31: -40854000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 284000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALAUNOS THERAPEUTICS, INC. · 2019-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Free cash flow: -41138000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -40854000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446d10k.htm#1733409 Filing: 000119312521063387 Input fundies:CapitalExpenditure: 284000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446d10k.htm#1738213 Filing: 000119312521063387 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 79.98 million Exact value Exact value: -79976000 USD 2020-01-01 – 2020-12-31: -79976000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALAUNOS THERAPEUTICS, INC. · 2020-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Net Income: -79976000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -79976000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-20211231.htm#3173906 Filing: 000095017022004972 The citation records this snapshot. The page link may show a newer release later.	−USD 57.01 million Exact value Exact value: -57013000 USD 2020-01-01 – 2020-12-31: -57013000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALAUNOS THERAPEUTICS, INC. · 2020-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Operating Cash Flow: -57013000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -57013000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-20211231.htm#2893296 Filing: 000095017022004972 The citation records this snapshot. The page link may show a newer release later.	USD 9.78 million Exact value Exact value: 9778000 USD 2020-01-01 – 2020-12-31: 9778000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALAUNOS THERAPEUTICS, INC. · 2020-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Capital Expenditure: 9778000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9778000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-20211231.htm#2900684 Filing: 000095017022004972 The citation records this snapshot. The page link may show a newer release later.	−USD 66.79 million Calculation and evidence -57013000 − 9778000 USD Exact free cash flow: -66791000 USD 2020-01-01 – 2020-12-31: -57013000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 9778000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALAUNOS THERAPEUTICS, INC. · 2020-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Free cash flow: -66791000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -57013000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-20211231.htm#2893296 Filing: 000095017022004972 Input fundies:CapitalExpenditure: 9778000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-20211231.htm#2900684 Filing: 000095017022004972 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 78.75 million Exact value Exact value: -78751000 USD 2021-01-01 – 2021-12-31: -78751000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALAUNOS THERAPEUTICS, INC. · 2021-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Net Income: -78751000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -78751000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017023006377/tcrt-20221231.htm#2528581 Filing: 000095017023006377 The citation records this snapshot. The page link may show a newer release later.	−USD 61.47 million Exact value Exact value: -61468000 USD 2021-01-01 – 2021-12-31: -61468000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALAUNOS THERAPEUTICS, INC. · 2021-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Operating Cash Flow: -61468000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -61468000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017023006377/tcrt-20221231.htm#2231514 Filing: 000095017023006377 The citation records this snapshot. The page link may show a newer release later.	USD 3.32 million Exact value Exact value: 3323000 USD 2021-01-01 – 2021-12-31: 3323000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALAUNOS THERAPEUTICS, INC. · 2021-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Capital Expenditure: 3323000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3323000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017023006377/tcrt-20221231.htm#2239505 Filing: 000095017023006377 The citation records this snapshot. The page link may show a newer release later.	−USD 64.79 million Calculation and evidence -61468000 − 3323000 USD Exact free cash flow: -64791000 USD 2021-01-01 – 2021-12-31: -61468000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 3323000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALAUNOS THERAPEUTICS, INC. · 2021-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Free cash flow: -64791000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -61468000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017023006377/tcrt-20221231.htm#2231514 Filing: 000095017023006377 Input fundies:CapitalExpenditure: 3323000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017023006377/tcrt-20221231.htm#2239505 Filing: 000095017023006377 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 37.73 million Exact value Exact value: -37730000 USD 2022-01-01 – 2022-12-31: -37730000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALAUNOS THERAPEUTICS, INC. · 2022-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Net Income: -37730000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -37730000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017024038868/tcrt-20231231.htm#1855037 Filing: 000095017024038868 The citation records this snapshot. The page link may show a newer release later.	−USD 29.23 million Exact value Exact value: -29232000 USD 2022-01-01 – 2022-12-31: -29232000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALAUNOS THERAPEUTICS, INC. · 2022-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Operating Cash Flow: -29232000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29232000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017024038868/tcrt-20231231.htm#1641505 Filing: 000095017024038868 The citation records this snapshot. The page link may show a newer release later.	USD 216,000 Exact value Exact value: 216000 USD 2022-01-01 – 2022-12-31: 216000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALAUNOS THERAPEUTICS, INC. · 2022-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Capital Expenditure: 216000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 216000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017024038868/tcrt-20231231.htm#1646341 Filing: 000095017024038868 The citation records this snapshot. The page link may show a newer release later.	−USD 29.45 million Calculation and evidence -29232000 − 216000 USD Exact free cash flow: -29448000 USD 2022-01-01 – 2022-12-31: -29232000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 216000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALAUNOS THERAPEUTICS, INC. · 2022-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Free cash flow: -29448000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29232000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017024038868/tcrt-20231231.htm#1641505 Filing: 000095017024038868 Input fundies:CapitalExpenditure: 216000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017024038868/tcrt-20231231.htm#1646341 Filing: 000095017024038868 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 4.68 million Exact value Exact value: -4679000 USD 2023-01-01 – 2023-12-31: -4679000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALAUNOS THERAPEUTICS, INC. · 2023-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Net Income: -4679000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4679000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1248268 Filing: 000119312526134720 The citation records this snapshot. The page link may show a newer release later.	−USD 30.14 million Exact value Exact value: -30142000 USD 2023-01-01 – 2023-12-31: -30142000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALAUNOS THERAPEUTICS, INC. · 2023-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Operating Cash Flow: -30142000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -30142000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017025047758/tcrt-20241231.htm#1672140 Filing: 000095017025047758 The citation records this snapshot. The page link may show a newer release later.	USD 197,000 Exact value Exact value: 197000 USD 2023-01-01 – 2023-12-31: 197000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALAUNOS THERAPEUTICS, INC. · 2023-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Capital Expenditure: 197000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 197000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017025047758/tcrt-20241231.htm#1678136 Filing: 000095017025047758 The citation records this snapshot. The page link may show a newer release later.	−USD 30.34 million Calculation and evidence -30142000 − 197000 USD Exact free cash flow: -30339000 USD 2023-01-01 – 2023-12-31: -30142000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 197000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALAUNOS THERAPEUTICS, INC. · 2023-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Free cash flow: -30339000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -30142000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017025047758/tcrt-20241231.htm#1672140 Filing: 000095017025047758 Input fundies:CapitalExpenditure: 197000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000095017025047758/tcrt-20241231.htm#1678136 Filing: 000095017025047758 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 4.68 million Exact value Exact value: -4679000 USD 2024-01-01 – 2024-12-31: -4679000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALAUNOS THERAPEUTICS, INC. · 2024-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Net Income: -4679000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4679000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1743136 Filing: 000119312526134720 The citation records this snapshot. The page link may show a newer release later.	−USD 4.97 million Exact value Exact value: -4971000 USD 2024-01-01 – 2024-12-31: -4971000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALAUNOS THERAPEUTICS, INC. · 2024-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Operating Cash Flow: -4971000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4971000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1547620 Filing: 000119312526134720 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALAUNOS THERAPEUTICS, INC. · 2024-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1554282 Filing: 000119312526134720 The citation records this snapshot. The page link may show a newer release later.	−USD 4.97 million Calculation and evidence -4971000 − 0 USD Exact free cash flow: -4971000 USD 2024-01-01 – 2024-12-31: -4971000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALAUNOS THERAPEUTICS, INC. · 2024-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Free cash flow: -4971000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4971000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1547620 Filing: 000119312526134720 Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1554282 Filing: 000119312526134720 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 4.18 million Exact value Exact value: -4176000 USD 2025-01-01 – 2025-12-31: -4176000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALAUNOS THERAPEUTICS, INC. · 2025-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Net Income: -4176000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4176000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1741275 Filing: 000119312526134720 The citation records this snapshot. The page link may show a newer release later.	−USD 2.87 million Exact value Exact value: -2869000 USD 2025-01-01 – 2025-12-31: -2869000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALAUNOS THERAPEUTICS, INC. · 2025-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Operating Cash Flow: -2869000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2869000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1545671 Filing: 000119312526134720 The citation records this snapshot. The page link may show a newer release later.	USD 98,000 Exact value Exact value: 98000 USD 2025-01-01 – 2025-12-31: 98000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALAUNOS THERAPEUTICS, INC. · 2025-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Capital Expenditure: 98000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 98000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1552538 Filing: 000119312526134720 The citation records this snapshot. The page link may show a newer release later.	−USD 2.97 million Calculation and evidence -2869000 − 98000 USD Exact free cash flow: -2967000 USD 2025-01-01 – 2025-12-31: -2869000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 98000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALAUNOS THERAPEUTICS, INC. · 2025-12-31 ALAUNOS THERAPEUTICS, INC. (edgar:1107421) Free cash flow: -2967000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:59:59Z Snapshot: eac42ba74c6154cb13be7c984cfc0e990db6b491cd7dac1552649dd203e0dbad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1107421?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2869000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1545671 Filing: 000119312526134720 Input fundies:CapitalExpenditure: 98000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/tcrt-20251231.htm#1552538 Filing: 000119312526134720 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

130 filings · 3,768 latest values · 3,768 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001107421, 1107421, TCRT, ZIOP, edgar:1107421

Also known as ALAUNOS THERAPEUTICS, INC., Alaunos Therapeutics, Inc., EASYWEB INC, ZIOPHARM ONCOLOGY INC, ZIOPHARM Oncology, Inc.

ALAUNOS THERAPEUTICS, INC.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation